CD274 and nasopharyngeal carcinoma: Nevertheless, the response rates of immunotherapies in NPC remain unsatisfactory, with 33% of PD-L1-positive cases and 13% of PD-L1-negative cases (Xu et al. 2022; Ma et al. 2018).